[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626009":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":25,"responsibleParty":40,"collaborators":42,"id":45,"slug":25,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":25,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":70,"whyStopped":25,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":25},{"fullName":5,"class":6},"Vivani Medical, Inc","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Semaglutide Implant (NPM-139)","EXPERIMENTAL","Each participants in this arm will receive one Semaglutide Implant (NPM-139) which will be inserted subcutaneously in the upper outer arm and subsequently removed after 4 weeks of treatment.",[13],"Combination Product: Semaglutide Implant (NPM-139)",{"label":15,"type":16,"description":17,"interventionNames":18},"Semaglutide (Wegovy) weekly injection","ACTIVE_COMPARATOR","Each participant in this arm will receive Semaglutide (Wegovy) 0.25 mg subcutaneous injection weekly for 4 weeks of treatment.",[19],"Drug: Semaglutide (Wegovy) weekly injection",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"COMBINATION_PRODUCT","Semaglutide Implant (NPM-139) is a drug\u002Fdevice combination product consisting of a subdermal titanium implant \\~23 mm long and 2 mm in diameter, containing a sterile liquid formulation of semaglutide that is released from the implant at a substantially constant rate over at least 15 weeks.",[9],null,{"type":27,"name":15,"description":28,"armGroupLabels":29,"otherNames":25},"DRUG","Semaglutide (Wegovy) is a clear, colorless solution provided as Wegovy FlexTouch four-dose pens: 0.25 mg\u002F0.5 mL. It is injected SC in the abdomen, thigh or upper arm once\u002Fweek.",[15],[31],{"name":32,"affiliation":5,"role":33},"Lisa Porter, MD","STUDY_DIRECTOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":25,"email":39},"Chief Medical Officer, MD","CONTACT","4155068462","clinical@vivanai.com",{"type":41,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[43],{"name":44,"class":6},"Avance Clinical Pty Ltd.","100626009",false,"NCT07430059","Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant","A Randomized, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Semaglutide Implant","SLIM-1","Inclusion Criteria:\n\n* BMI between 27 and 40 kg\u002Fm2 (inclusive)\n* HbA1c \\\u003C\u002F= 6.0% and FPG \\\u003C\u002F+ 6.7 mmil\u002FL\n* eGFR \\>\u002F= 60 mL\u002Fm2\n* No significant health issues in the opinion of the Investigator that would preclude study participation, as determined by medical history and physical examination\n\nExclusion Criteria:\n\n* Type 1 or Type 2 Diabetesa\n* A clinically significant medical condition that could potentially affect study participation and\u002For personal well-being, as judged by the Investigator\n* Treatment with glucose lowering agent(s) within 3 months before Screening","ALL","18 Years","60 Years",{"count":56,"type":57},20,"ESTIMATED","INTERVENTIONAL",[60],"PHASE1","The study will evaluate the safety, tolerability and drug levels of a semaglutide implant placed just under the skin for a period of 4 weeks compared to 4 weekly injections of semaglutide (Wegovy) in overweight\u002Fobese participants who are otherwise healthy..",[63],"Obesity & Overweight",[65,66,67,68,69],"obesity","overweight","semaglutide","implant","glp-1","NOT_YET_RECRUITING","2026-06-25",{"date":73,"type":74},"2026-06-30","ACTUAL",{"date":76,"type":57},"2026-07",{"date":78,"type":57},"2027-01",{"name":5,"class":6}]